The use of generic, biosimilar and non-biologic complex drugs for multiple sclerosis (Certified by ParadigMS)
About this e-learning
Welcome to our e-learning on “The Use of Generics, Biosimilars, and NBCDs in the Treatment of Multiple Sclerosis (MS).”
With the increasing prevalence of MS and the high cost of treatment, generics, biosimilars, and non-biologic complex drugs (NBCDs) offer promising, cost-effective alternatives to originator therapies. Understanding these therapies is vital for healthcare providers, as it impacts treatment accessibility, patient outcomes, and healthcare economics.
This course, led by Prof. Thomas Berger and Prof. Celia Oreja-Guevara, will provide you with essential insights into the regulatory standards, real-world data, and clinical applications of these therapies. Learning about generics, biosimilars, and NBCDs is crucial in supporting informed decision-making, ensuring patient safety, and optimizing treatment strategies for individuals with MS.
Certificate
Participants will gain a ParadigMS Foundation Certificate upon completion, though please note that EACCME accreditation is not be available for this e-learning.
Learning objectives
Prof. Thomas Berger – Understanding the Basics of Generics, Biosimilars, and NBCDs
In this segment, Prof. Thomas Berger from the Medical University of Vienna covers the fundamentals of generics, biosimilars, and NBCDs. His presentation focuses on the regulatory landscape, key definitions, and essential differences between these treatments and their originator drugs.
Learning Objectives:
- Recognize the potential advantages and limitations of integrating these therapies into clinical practice.
- Define generics, biosimilars, and NBCDs and understand their unique roles in MS treatment.
- Understand regulatory requirements and approval processes for each type.
Prof. Celia Oreja-Guevara – Clinical Application and Real-World Data
Prof. Celia Oreja-Guevara from the Hospital Clínico San Carlos in Madrid provides a clinical perspective, exploring real-world data on the use of generics, biosimilars, and NBCDs in MS treatment. Her session examines patient satisfaction, adherence rates, and case studies, highlighting practical strategies for incorporating these treatments effectively.
Learning Objectives:
- Examine real-world data on the effectiveness and safety of generics and biosimilars in MS.
- Learn strategies for managing patient expectations and adherence.
- Discuss best practices for monitoring and pharmacovigilance when using these therapies.
